Cargando…

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials

IMPORTANCE: Migraine with aura may respond differently to therapies than migraine without aura. Individuals with migraine with aura have an elevated vascular risk, necessitating a safety assessment of migraine preventive treatments in this patient subgroup. OBJECTIVE: To assess the efficacy and safe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ashina, Messoud, Goadsby, Peter J., Dodick, David W., Tepper, Stewart J., Xue, Fei, Zhang, Feng, Brennan, Francis, Paiva da Silva Lima, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689443/ https://www.ncbi.nlm.nih.gov/pubmed/34928306 http://dx.doi.org/10.1001/jamaneurol.2021.4678

Ejemplares similares

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
por: Ashina, Messoud, et al.
Publicado: (2019)

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
por: Diener, Hans-Christoph, et al.
Publicado: (2021)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial
por: Tepper, Stewart J., et al.
Publicado: (2019)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

EHMTI-0039. Different efficacy of acute migraine therapies for migraine with aura versus without aura
por: Hansen, J Møller, et al.
Publicado: (2014)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
por: Tepper, Stewart J, et al.
Publicado: (2021)

Calcitonin gene-related peptide causes migraine aura
por: Al-Khazali, Haidar M., et al.
Publicado: (2023)

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis
por: Ashina, Messoud, et al.
Publicado: (2022)

Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data
por: Dodick, David W., et al.
Publicado: (2021)

Migraine headache is present in the aura phase – a prospective study
por: Hansen, JM, et al.
Publicado: (2013)

Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura
por: Antonova, M, et al.
Publicado: (2013)

Sensory migraine aura is not associated with structural grey matter abnormalities
por: Hougaard, Anders, et al.
Publicado: (2016)

Evaluating migraine with typical aura with neuroimaging
por: Karsan, Nazia, et al.
Publicado: (2023)

Migraine aura‐like episodes following sclerotherapy for varicose veins of the lower extremities—A systematic review
por: Bahtiri, Lionesa, et al.
Publicado: (2023)

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
por: Ashina, Messoud, et al.
Publicado: (2022)

A genetic risk score is differentially associated with migraine with and without aura
por: Pisanu, Claudia, et al.
Publicado: (2017)

Migraine aura without headache compared to migraine with aura in patients with affective disorders
por: Oedegaard, K. J., et al.
Publicado: (2005)

Interictal pontine metabolism in migraine without aura patients: A 3 Tesla proton magnetic resonance spectroscopy study
por: Younis, Samaira, et al.
Publicado: (2021)

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study
por: Cullum, Christopher Kjaer, et al.
Publicado: (2022)

Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study
por: Amin, Faisal Mohammad, et al.
Publicado: (2021)

Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study
por: Ferrari, Michel Dominique, et al.
Publicado: (2022)

Migraine without aura is not associated with incomplete circle of Willis: a case–control study using high-resolution magnetic resonance angiography
por: Ezzatian-Ahar, Shabnam, et al.
Publicado: (2014)

Correction: Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study
por: Amin, Faisal Mohammad, et al.
Publicado: (2023)

Migraine with aura in women is not associated with structural thalamic abnormalities
por: Hougaard, Anders, et al.
Publicado: (2020)

Provocation of migraine with aura using natural trigger factors
por: Hougaard, A, et al.
Publicado: (2013)

Is Ciliary Muscle Affected in Migraine Patients with Aura and without Aura?
por: Kıvanç, Sertaç Argun, et al.
Publicado: (2015)

EHMTI-0044. Variability of clinical features in attacks of migraine with aura
por: Hansen, J Møller, et al.
Publicado: (2014)

New onset migraine with aura after treatment initiation with ivabradine
por: Sprenger, Till, et al.
Publicado: (2013)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
por: Manickam, Agaath Hedina, et al.
Publicado: (2021)

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
por: Lipton, Richard B., et al.
Publicado: (2019)

Should migraine without aura be further divided? A study of 1444 female patients with migraine without aura
por: Wang, Xiaolin, et al.
Publicado: (2023)

Conversion from migraine without aura to typical aura without headache after irbesartan
por: Pinessi, L., et al.
Publicado: (2005)

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Migraine with aura and risk of silent brain infarcts and white matter hyperintensities: an MRI study
por: Gaist, David, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ecp8fp1cv6h6c1m6lpa0kt1cfl